Direkt zum Inhalt
Merck
  • Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis.

Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis.

Antimicrobial agents and chemotherapy (2011-11-23)
Thomas Grau, Petra Selchow, Marcel Tigges, Reto Burri, Marc Gitzinger, Erik C Böttger, Martin Fussenegger, Peter Sander
ZUSAMMENFASSUNG

Ethionamide (ETH) is a second-line drug for the treatment of tuberculosis. As a prodrug, ETH has to be activated by EthA. ethA is controlled by its repressor EthR. 2-Phenylethyl-butyrate (2-PEB) inhibits EthR binding, enhances expression of EthA, and thereby enhances the growth-inhibitory effects of ethionamide, isoxyl, and thiacetazone in Mycobacterium tuberculosis strains with resistance to ETH due to inhA promoter mutations but not ethA mutations.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
N-Phenylthioharnstoff, ≥98%
Sigma-Aldrich
Ethionamid